Balance Sheet Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 16/01/2026 am IST			5-day change	1st Jan Change
133.35 ^USD	-1.46%		-1.64%	-5.98%

15/01	Neurocrine Biosciences, Inc. Presents Head-To-Head INGREZZA (Valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR	CI
15/01	Neurocrine Biosciences, Inc. Presents Head-To-Head INGREZZA (Valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR	CI

bc268a989db4e3f5bc642b25a39.el9EYcr8u_ZWINI2DGNmPCl70juM1o24xK57J2zOoYY.OW4pVZmywoYTTZt4ZjYDd3Ek4XC0gu7O_dwBVBqm--pPPDQpgKzTnDxMtQ

Published financial data: NEUROCRINE BIOSCIENCES, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020	2021	2022	2023	2024
Revenues	104.59Cr	113.35Cr	148.87Cr	188.71Cr	235.53Cr
Total Revenues	104.59Cr	113.35Cr	148.87Cr	188.71Cr	235.53Cr
Cost of Goods Sold, Total	29Cr	34Cr	49Cr	60Cr	77Cr
Gross Profit	76Cr	79Cr	100.17Cr	128.24Cr	159.02Cr
Selling General & Admin Expenses, Total	43Cr	58Cr	75Cr	89Cr	100.72Cr
R&D Expenses	-	-	-	-	-
Other Operating Expenses, Total	43Cr	58Cr	75Cr	89Cr	100.72Cr
Operating Income	33Cr	21Cr	25Cr	39Cr	58Cr
Interest Expense, Total	-3.28Cr	-2.58Cr	-71L	-46L	-
Interest And Investment Income	1.26Cr	38L	1.12Cr	5.74Cr	9.1Cr
Net Interest Expenses	-2.02Cr	-2.2Cr	41L	5.28Cr	9.1Cr
Other Non Operating Income (Expenses)	-	-	-	-	-
EBT, Excl. Unusual Items	31Cr	19Cr	25Cr	45Cr	67Cr
Gain (Loss) On Sale Of Investments	-1.77Cr	2.09Cr	3.08Cr	2.84Cr	-3.71Cr
Gain (Loss) On Sale Of Assets	-	-	-	-	-
In Process R&D Expenses	-16Cr	-11Cr	-	-14Cr	-1.25Cr
Other Unusual Items	-1.84Cr	-	-7Cr	-	-14Cr
EBT, Incl. Unusual Items	11Cr	10Cr	21Cr	33Cr	49Cr
Income Tax Expense	-30Cr	1.18Cr	5.94Cr	8.24Cr	14Cr
Earnings From Continuing Operations	41Cr	8.96Cr	15Cr	25Cr	34Cr
Net Income to Company	41Cr	8.96Cr	15Cr	25Cr	34Cr
Net Income - (IS)	41Cr	8.96Cr	15Cr	25Cr	34Cr
Net Income to Common Incl Extra Items	41Cr	8.96Cr	15Cr	25Cr	34Cr
Net Income to Common Excl. Extra Items	41Cr	8.96Cr	15Cr	25Cr	34Cr
Per Share Items
Net EPS - Basic	4.37	0.95	1.61	2.56	3.4
Basic EPS - Continuing Operations	4.37	0.95	1.61	2.56	3.4
Basic Weighted Average Shares Outstanding	9.31Cr	9.46Cr	9.58Cr	9.77Cr	10Cr
Net EPS - Diluted	4.16	0.92	1.56	2.47	3.29
Diluted EPS - Continuing Operations	4.16	0.92	1.56	2.47	3.29
Diluted Weighted Average Shares Outstanding	9.78Cr	9.79Cr	9.89Cr	10Cr	10Cr
Normalized Basic EPS	2.06	1.23	1.65	2.86	4.2
Normalized Diluted EPS	1.96	1.19	1.6	2.77	4.06
American Depositary Receipts Ratio (ADR)	0.05	0.05	0.05	0.05	0.05
Supplemental Items
EBITDA	34Cr	22Cr	26Cr	42Cr	61Cr
EBITA	33Cr	21Cr	25Cr	40Cr	59Cr
EBIT	33Cr	21Cr	25Cr	39Cr	58Cr
EBITDAR	35Cr	23Cr	28Cr	43Cr	65Cr
Total Revenues (As Reported)	104.59Cr	113.35Cr	148.87Cr	188.71Cr	235.53Cr
Effective Tax Rate - (Ratio)	-281.72	11.64	27.77	24.81	29.77
Current Domestic Taxes	1.01Cr	63L	3.74Cr	14Cr	27Cr
Total Current Taxes	1.01Cr	63L	3.74Cr	14Cr	27Cr
Deferred Domestic Taxes	-31Cr	55L	2.2Cr	-5.07Cr	-12Cr
Total Deferred Taxes	-31Cr	55L	2.2Cr	-5.07Cr	-12Cr
Normalized Net Income	19Cr	12Cr	16Cr	28Cr	42Cr
Interest on Long-Term Debt	-	-	-	46L	-
Supplemental Operating Expense Items
Advertising Expense	6.48Cr	14Cr	15Cr	16Cr	19Cr
Selling and Marketing Expenses	-	-	-	-	19Cr
General and Administrative Expenses	-	-	-	-	-
Research And Development Expense From Footnotes	44Cr	43Cr	46Cr	71Cr	74Cr
Net Rental Expense, Total	1.01Cr	1.53Cr	1.63Cr	1.64Cr	4.16Cr
Imputed Operating Lease Interest Expense	57.73L	72.66L	25.69L	16.69L	-
Imputed Operating Lease Depreciation	43.27L	80.34L	1.37Cr	1.47Cr	-
Stock-Based Comp., COGS (Total)	3.37Cr	4.84Cr	5.77Cr	6.8Cr	6.88Cr
Stock-Based Comp., R&D Exp. (Total)	-	-	-	-	-
Stock-Based Comp., G&A Exp. (Total)	-	-	-	-	-
Stock-Based Comp., SG&A Exp. (Total)	6.63Cr	8.58Cr	12Cr	13Cr	13Cr
Total Stock-Based Compensation	10Cr	13Cr	17Cr	19Cr	20Cr

Fiscal Period: December	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	19Cr	34Cr	26Cr	25Cr	23Cr
Short Term Investments	61Cr	37Cr	73Cr	78Cr	84Cr
Total Cash And Short Term Investments	80Cr	71Cr	99Cr	103.16Cr	107.61Cr
Accounts Receivable, Total	16Cr	19Cr	35Cr	44Cr	48Cr
Total Receivables	16Cr	19Cr	35Cr	44Cr	48Cr
Inventory	2.8Cr	3.05Cr	3.51Cr	3.83Cr	5.74Cr
Other Current Assets, Total	3.01Cr	4.55Cr	7.91Cr	9.78Cr	11Cr
Total Current Assets	101.62Cr	97Cr	145.35Cr	160.7Cr	172.47Cr
Gross Property Plant And Equipment	17Cr	21Cr	21Cr	43Cr	70Cr
Accumulated Depreciation	-4.17Cr	-5.19Cr	-6.63Cr	-8.3Cr	-11Cr
Net Property Plant And Equipment	13Cr	16Cr	15Cr	35Cr	59Cr
Long-term Investments	27Cr	62Cr	40Cr	85Cr	86Cr
Goodwill	-	-	-	58L	57L
Other Intangibles, Total	-	-	3.72Cr	3.55Cr	3.65Cr
Deferred Tax Assets Long-Term	32Cr	32Cr	31Cr	36Cr	49Cr
Other Long-Term Assets, Total	64L	44L	2.5Cr	4.38Cr	98L
Total Assets	173.47Cr	207.25Cr	236.87Cr	325.14Cr	371.87Cr
Liabilities
Accounts Payable, Total	3.94Cr	5.15Cr	7.63Cr	11Cr	11Cr
Accrued Expenses, Total	9.47Cr	11Cr	14Cr	32Cr	35Cr
Current Portion of Long-Term Debt	-	-	17Cr	17Cr	-
Current Portion of Leases	1.03Cr	1.65Cr	1.74Cr	3.2Cr	4.06Cr
Current Income Taxes Payable	-	-	-	2.44Cr	-
Unearned Revenue Current, Total	3.46Cr	6.27Cr	13Cr	-	-
Other Current Liabilities	75L	35L	33L	39L	55L
Total Current Liabilities	19Cr	25Cr	54Cr	65Cr	51Cr
Long-Term Debt	32Cr	34Cr	-	-	-
Long-Term Leases	9.44Cr	11Cr	9.35Cr	26Cr	46Cr
Unearned Revenue Non Current	-	-	-	-	-
Other Non Current Liabilities	97L	1.23Cr	2.97Cr	11Cr	17Cr
Total Liabilities	61Cr	70Cr	66Cr	101.94Cr	112.9Cr
Common Stock, Total	1L	1L	1L	1L	1L
Additional Paid In Capital	184.97Cr	201.14Cr	212.24Cr	238.2Cr	255.46Cr
Retained Earnings	-73Cr	-64Cr	-41Cr	-16Cr	2.92Cr
Comprehensive Income and Other	18L	-17L	-79L	70L	58L
Total Common Equity	112.62Cr	137.4Cr	170.78Cr	223.2Cr	258.97Cr
Total Equity	112.62Cr	137.4Cr	170.78Cr	223.2Cr	258.97Cr
Total Liabilities And Equity	173.47Cr	207.25Cr	236.87Cr	325.14Cr	371.87Cr
Supplemental Items
ECS Total Shares Outstanding on Filing Date	9.39Cr	9.52Cr	9.66Cr	9.95Cr	9.97Cr
ECS Total Common Shares Outstanding	9.35Cr	9.49Cr	9.65Cr	9.87Cr	9.94Cr
Book Value / Share	12.04	14.48	17.7	22.61	26.05
Tangible Book Value	112.62Cr	137.4Cr	167.06Cr	219.07Cr	254.75Cr
Tangible Book Value Per Share	12.04	14.48	17.31	22.2	25.63
Total Debt	42Cr	46Cr	28Cr	46Cr	50Cr
Net Debt	-38Cr	-25Cr	-71Cr	-57Cr	-58Cr
Debt Equivalent Oper. Leases	8.08Cr	12Cr	13Cr	13Cr	33Cr
Account Code - Inventory Valuation	5	5	5	5	5
Inventories - Raw Materials, Total	1.66Cr	1.12Cr	1.2Cr	2.15Cr	3.37Cr
Inventories - Work In Process, Total	24L	36L	56L	97L	1.09Cr
Inventories - Finished Goods, Total	90L	1.57Cr	1.75Cr	1.23Cr	1.28Cr
Machinery, Total	5.68Cr	7.56Cr	8.7Cr	12Cr	15Cr
Full Time Employees	845	900	1.2T	1.4T	1.8T

Fiscal Period: December	2020	2021	2022	2023	2024
Net Income	41Cr	8.96Cr	15Cr	25Cr	34Cr
Depreciation & Amortization - CF	86L	1.09Cr	1.51Cr	1.78Cr	2.35Cr
Amortization of Goodwill and Intangible Assets - (CF)	-	-	5L	35L	36L
Depreciation & Amortization, Total	86L	1.09Cr	1.56Cr	2.13Cr	2.71Cr
Amortization of Deferred Charges, Total - (CF)	2.14Cr	1.73Cr	12L	7L	-
(Gain) Loss From Sale Of Asset	-	-	-	-	-
(Gain) Loss on Sale of Investments - (CF)	1.77Cr	-2.09Cr	-3.08Cr	-4.67Cr	1.09Cr
Stock-Based Compensation (CF)	10Cr	13Cr	17Cr	19Cr	20Cr
Other Operating Activities, Total	-29Cr	87L	9.32Cr	-5.76Cr	3.98Cr
Change In Accounts Receivable	-3.05Cr	-2.84Cr	-16Cr	-8.93Cr	-3.98Cr
Change In Inventories	-1.07Cr	-25L	-26L	54L	-1.91Cr
Change In Accounts Payable	2.69Cr	5.68Cr	11Cr	6.43Cr	2.9Cr
Change in Other Net Operating Assets	-2.36Cr	-92L	-1.72Cr	4.78Cr	1.07Cr
Cash from Operations	23Cr	26Cr	34Cr	39Cr	60Cr
Capital Expenditure	-1.09Cr	-2.34Cr	-1.65Cr	-2.83Cr	-3.82Cr
Sale of Property, Plant, and Equipment	-	-	-	-	-
Cash Acquisitions	-	-	-4.27Cr	-	-
Investment in Marketable and Equity Securities, Total	1.5Cr	-10Cr	-11Cr	-44Cr	-8.86Cr
Other Investing Activities, Total	-	-46L	-77L	-	-
Cash from Investing	41L	-13Cr	-18Cr	-47Cr	-13Cr
Long-Term Debt Issued, Total	-	-	-	-	-
Total Debt Issued	-	-	-	-	-
Long-Term Debt Repaid, Total	-19Cr	-1L	-28Cr	-	-31Cr
Total Debt Repaid	-19Cr	-1L	-28Cr	-	-31Cr
Issuance of Common Stock	2.91Cr	2.75Cr	4.47Cr	6.53Cr	12Cr
Repurchase of Common Stock	-	-	-	-	-30Cr
Cash from Financing	-16Cr	2.74Cr	-23Cr	6.53Cr	-49Cr
Foreign Exchange Rate Adjustments	-	-	-13L	3L	-
Net Change in Cash	7.48Cr	15Cr	-7.33Cr	-1.16Cr	-1.81Cr
Supplemental Items
Cash Interest Paid	1.16Cr	86L	66L	38L	16L
Cash Income Tax Paid (Refund)	1.53Cr	51L	1.44Cr	5.15Cr	22Cr
Levered Free Cash Flow	27Cr	25Cr	23Cr	41Cr	46Cr
Unlevered Free Cash Flow	27Cr	25Cr	23Cr	41Cr	46Cr
Change In Net Working Capital	3.5Cr	35L	9.76Cr	2.68Cr	9.08Cr
Net Debt Issued / Repaid	-19Cr	-1L	-28Cr	-	-31Cr

Fiscal Period: December	2020	2021	2022	2023	2024
Profitability
Return on Assets	13.46	6.82	7.01	8.78	10.46
Return on Total Capital	15.27	7.71	8.19	10.58	12.68
Return On Equity %	46.2	7.17	10.03	12.68	14.16
Return on Common Equity	46.2	7.17	10.03	12.68	14.16
Margin Analysis
Gross Profit Margin %	72.74	69.79	67.29	67.96	67.52
SG&A Margin	41.43	51.46	50.56	47.04	42.76
EBITDA Margin %	32.14	19.29	17.77	22.05	25.9
EBITA Margin %	31.31	18.33	16.76	21.11	24.91
EBIT Margin %	31.31	18.33	16.73	20.92	24.75
Income From Continuing Operations Margin %	38.94	7.9	10.38	13.23	14.49
Net Income Margin %	38.94	7.9	10.38	13.23	14.49
Net Avail. For Common Margin %	38.94	7.9	10.38	13.23	14.49
Normalized Net Income Margin	18.36	10.24	10.63	14.82	17.89
Levered Free Cash Flow Margin	25.65	21.99	15.25	21.47	19.44
Unlevered Free Cash Flow Margin	25.57	21.89	15.46	21.58	19.44
Asset Turnover
Asset Turnover	0.69	0.6	0.67	0.67	0.68
Fixed Assets Turnover	8.59	8	9.88	7.66	5.02
Receivables Turnover (Average Receivables)	7.37	6.62	5.56	4.78	5.13
Inventory Turnover (Average Inventory)	12.59	11.71	14.85	16.48	15.99
Short Term Liquidity
Current Ratio	5.45	3.96	2.7	2.45	3.4
Quick Ratio	5.14	3.65	2.49	2.25	3.06
Operating Cash Flow to Current Liabilities	1.23	1.04	0.63	0.6	1.17
Days Sales Outstanding (Average Receivables)	49.64	55.16	65.65	76.33	71.36
Days Outstanding Inventory (Average Inventory)	29.08	31.18	24.58	22.15	22.89
Average Days Payable Outstanding	49.99	48.1	47.44	52.9	56.78
Cash Conversion Cycle (Average Days)	28.73	38.24	42.79	45.59	37.47
Long Term Solvency
Total Debt/Equity	37.52	33.25	16.41	20.63	19.14
Total Debt / Total Capital	27.29	24.95	14.1	17.1	16.07
LT Debt/Equity	36.61	32.05	5.47	11.57	17.57
Long-Term Debt / Total Capital	26.62	24.05	4.7	9.59	14.75
Total Liabilities / Total Assets	35.08	33.7	27.9	31.35	30.36
EBIT / Interest Expense	9.98	8.05	35.07	85.83	-
EBITDA / Interest Expense	10.55	9.07	39.56	94.02	-
(EBITDA - Capex) / Interest Expense	10.22	8.16	37.24	87.87	-
Total Debt / EBITDA	1.22	1.95	1	1.06	0.76
Net Debt / EBITDA	-1.09	-1.09	-2.52	-1.32	-0.89
Total Debt / (EBITDA - Capex)	1.26	2.17	1.06	1.14	0.81
Net Debt / (EBITDA - Capex)	-1.13	-1.21	-2.68	-1.41	-0.95
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	32.71	8.38	31.34	26.76	24.81
Gross Profit, 1 Yr. Growth %	31.01	3.98	26.62	28.02	24
EBITDA, 1 Yr. Growth %	43.63	-34.93	20.99	57.26	46.62
EBITA, 1 Yr. Growth %	44.53	-36.55	20.07	59.64	47.28
EBIT, 1 Yr. Growth %	44.53	-36.55	19.83	58.55	47.67
Earnings From Cont. Operations, 1 Yr. Growth %	1T	-78	72.43	61.62	36.68
Net Income, 1 Yr. Growth %	1T	-78	72.43	61.62	36.68
Normalized Net Income, 1 Yr. Growth %	43.73	-39.54	36.22	76.85	50.58
Diluted EPS Before Extra, 1 Yr. Growth %	966.67	-77.88	69.57	58.33	33.2
Accounts Receivable, 1 Yr. Growth %	24.09	18.08	88.68	25.51	9.06
Inventory, 1 Yr. Growth %	61.85	8.93	15.08	9.12	49.87
Net Property, Plant and Equip., 1 Yr. Growth %	9.64	22.29	-6.55	138.53	70.46
Total Assets, 1 Yr. Growth %	32.83	19.47	14.29	37.27	14.37
Tangible Book Value, 1 Yr. Growth %	76.83	22	21.59	31.56	16.29
Common Equity, 1 Yr. Growth %	76.83	22	24.29	30.69	16.03
Cash From Operations, 1 Yr. Growth %	55.44	12.25	32.32	14.88	52.71
Capital Expenditures, 1 Yr. Growth %	-25.85	114.68	-29.49	71.52	34.98
Levered Free Cash Flow, 1 Yr. Growth %	31.16	-10.53	-14.59	65.75	4.26
Unlevered Free Cash Flow, 1 Yr. Growth %	30.91	-10.66	-12.98	64.46	4.26
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	52.25	19.93	19.3	29.03	25.78
Gross Profit, 2 Yr. CAGR %	61.83	16.72	14.74	27.32	26
EBITDA, 2 Yr. CAGR %	171.49	-3.32	-11.27	37.94	51.85
EBITA, 2 Yr. CAGR %	180.58	-4.24	-12.72	38.45	53.33
EBIT, 2 Yr. CAGR %	180.58	-4.24	-12.8	37.84	53.02
Earnings From Cont. Operations, 2 Yr. CAGR %	339.36	55.62	-38.41	66.94	48.63
Net Income, 2 Yr. CAGR %	339.36	55.62	-38.41	66.94	48.63
Normalized Net Income, 2 Yr. CAGR %	239.89	-6.78	-9.25	55.21	63.19
Diluted EPS Before Extra, 2 Yr. CAGR %	334.85	53.59	-38.76	63.85	45.22
Accounts Receivable, 2 Yr. CAGR %	65.43	21.05	49.26	53.89	17
Inventory, 2 Yr. CAGR %	60.54	32.78	11.96	12.06	27.88
Net Property, Plant and Equip., 2 Yr. CAGR %	93.95	15.79	6.9	49.3	101.64
Total Assets, 2 Yr. CAGR %	32.16	25.97	16.85	25.25	25.3
Tangible Book Value, 2 Yr. CAGR %	53.05	46.88	21.79	26.27	23.69
Common Equity, 2 Yr. CAGR %	53.05	46.88	23.14	27.45	23.14
Cash From Operations, 2 Yr. CAGR %	50.12	32.09	21.87	23.29	32.45
Capital Expenditures, 2 Yr. CAGR %	-33.7	26.17	23.04	9.97	52.16
Levered Free Cash Flow, 2 Yr. CAGR %	133.82	10.39	-9.73	23.46	36
Unlevered Free Cash Flow, 2 Yr. CAGR %	133.05	10.21	-8.95	24.07	36
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	86.35	35.94	23.62	21.74	27.61
Gross Profit, 3 Yr. CAGR %	123.07	39.65	19.93	19.01	26.2
EBITDA, 3 Yr. CAGR %	50.31	68.64	4.18	7.38	40.77
EBITA, 3 Yr. CAGR %	47.84	70.94	3.26	6.74	41.33
EBIT, 3 Yr. CAGR %	47.84	70.94	3.19	6.43	41.04
Earnings From Cont. Operations, 3 Yr. CAGR %	41.9	61.94	61.03	-15.05	56.17
Net Income, 3 Yr. CAGR %	41.9	61.94	61.03	-15.05	56.17
Normalized Net Income, 3 Yr. CAGR %	39.77	91.16	5.79	13.36	53.65
Diluted EPS Before Extra, 3 Yr. CAGR %	36.94	61.11	58.74	-15.95	52.92
Accounts Receivable, 3 Yr. CAGR %	71.53	47.84	40.35	40.88	37.2
Inventory, 3 Yr. CAGR %	201.27	41.07	26.6	11.01	23.46
Net Property, Plant and Equip., 3 Yr. CAGR %	127.56	66.31	7.81	39.69	56.05
Total Assets, 3 Yr. CAGR %	28.5	27.79	21.95	23.3	21.52
Tangible Book Value, 3 Yr. CAGR %	44.65	41.91	37.91	24.83	22.85
Common Equity, 3 Yr. CAGR %	44.65	41.91	38.93	25.61	23.52
Cash From Operations, 3 Yr. CAGR %	34.3	36.25	32.17	19.5	32.41
Capital Expenditures, 3 Yr. CAGR %	16.24	-1.92	3.93	37.44	17.75
Levered Free Cash Flow, 3 Yr. CAGR %	92.4	71.9	3.53	13.29	19.89
Unlevered Free Cash Flow, 3 Yr. CAGR %	92.89	71.44	4.07	13.61	20.07
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	121.16	137.5	55.9	33.13	24.48
Gross Profit, 5 Yr. CAGR %	122.25	106.83	70.98	34.58	22.32
EBITDA, 5 Yr. CAGR %	29.25	8.43	21.74	55.61	21.13
EBITA, 5 Yr. CAGR %	28.3	7.11	19.74	57.12	20.95
EBIT, 5 Yr. CAGR %	28.3	7.11	19.69	56.84	20.8
Earnings From Cont. Operations, 5 Yr. CAGR %	35.57	-8.68	1.62	63.92	55.95
Net Income, 5 Yr. CAGR %	35.57	-8.68	1.62	63.92	55.95
Normalized Net Income, 5 Yr. CAGR %	27.21	6.2	17.6	75.87	25.81
Diluted EPS Before Extra, 5 Yr. CAGR %	31.64	-10.81	-0.75	62.2	53.19
Accounts Receivable, 5 Yr. CAGR %	-	-	62.25	50.23	30.5
Inventory, 5 Yr. CAGR %	-	-	102.77	28.66	27.11
Net Property, Plant and Equip., 5 Yr. CAGR %	106.03	90.13	68.21	59.29	38.49
Total Assets, 5 Yr. CAGR %	29.58	41.52	23.71	26.77	23.28
Tangible Book Value, 5 Yr. CAGR %	21.55	34.27	35.03	35.43	31.95
Common Equity, 5 Yr. CAGR %	21.55	34.27	35.63	35.94	32.38
Cash From Operations, 5 Yr. CAGR %	43.16	19.29	29.18	30.91	32.28
Capital Expenditures, 5 Yr. CAGR %	41.32	41.62	18.91	2.68	21.05
Levered Free Cash Flow, 5 Yr. CAGR %	65.14	33.04	43.22	52.53	17.49
Unlevered Free Cash Flow, 5 Yr. CAGR %	65.02	32.91	43.94	52.59	17.53